Sermorelin

What it is

Sermorelin is a synthetic copy of amino acids 1 through 29 of human growth hormone-releasing hormone, or GHRH. That short fragment retains the hormone's ability to signal the pituitary gland to release growth hormone.

The FDA previously approved sermorelin acetate products under the Geref name for diagnostic and pediatric uses. The manufacturer discontinued them, and FDA later determined that the withdrawal was not for safety or effectiveness reasons. There is no currently marketed FDA-approved sermorelin product, so a compounded vial or research vial is not the former branded drug.

What people research it for

How it works

Sermorelin activates GHRH receptors on growth-hormone-producing cells in the anterior pituitary. That signal prompts release of the body's own stored growth hormone and can raise downstream insulin-like growth factor 1, or IGF-1.

This is different from supplying growth hormone directly. Sermorelin depends on a pituitary that can still respond, which is why an apparently normal response could not rule out every form of growth hormone deficiency. Its short presence in circulation also does not by itself establish a durable clinical effect.

What the research actually shows

The largest clearly described treatment study enrolled 110 previously untreated prepubertal children with growth hormone deficiency in a one-year multicenter, open-label study. Eighty-six were eligible for efficacy analysis. Mean height velocity rose from 4.1 cm per year at baseline to 8.0 cm per year at six months and 7.2 cm per year at 12 months. Seventy-four percent met the study's good-response definition at six months.

That trial was not randomized or placebo controlled. It reported no adverse changes in general chemistry or hormone testing, no change in fasting glucose, and no excessive IGF-1 generation over the study period. Those findings are reassuring for that pediatric setting but do not settle long-term or adult safety.

A smaller study followed 18 prepubertal children with idiopathic short stature for one year. Seventeen completed at least three months. Mean height velocity increased from 4.8 to 7.2 cm per year, and predicted final height increased by 3.4 cm on average. Growth slowed after treatment ended and returned near the pretreatment rate by 12 months off treatment.

A drug review concluded that sermorelin could provoke a growth hormone response and might promote growth in some prepubertal children with idiopathic growth hormone deficiency. It also noted important limits: the effect on final adult height was unknown, response was not directly compared with the standard once-daily somatropin regimen, and some sermorelin regimens produced smaller gains than somatropin.

The FDA record adds essential regulatory context. Geref was discontinued by its manufacturer, and FDA determined that the products were not withdrawn for safety or effectiveness reasons. A later FDA-supported evidence report stated that no FDA-approved sermorelin product was currently available. These records do not convert today's compounded or research products into approved equivalents.

Claims about anti-aging, muscle gain, fat loss, sleep, or general adult wellness extend beyond the pediatric and diagnostic evidence summarized here. Reliable modern randomized trials demonstrating those outcomes were not found for sermorelin itself.

Handling & storage

Current sermorelin products do not share one FDA-approved finished formulation, so storage instructions must follow the exact supplier or dispensing label. Two checked handling sources agree that mixed sermorelin should be kept refrigerated at 2 to 8°C and protected from light. Their 28-day window is product and vendor guidance, not a published stability assay that applies to every vial.

Dry-powder instructions conflict. One vendor recommends -20°C for long-term research storage, while a compounding pharmacy lists 2 to 8°C for its lyophilized product. That difference is why the card does not claim one universal shelf life. Heat, light, moisture, and repeated freeze-thaw cycles should be avoided, and cloudy or particle-containing solutions should not be treated as usable research material.

Safety & cautions

Frequently asked questions

Sources

• Prakash and Goa, sermorelin clinical review
• Geref International Study Group, one-year pediatric study
• GHRH 1-29 study in idiopathic short stature
• FDA Federal Register notice on Geref withdrawal
• FDA-supported M-CERSI sermorelin evidence report
• Palmetto sermorelin handling guide
• FormBlends sermorelin handling guide
• Wells Pharmacy sermorelin vial information

Last reviewed September 17, 2026. This guide is educational and research-focused, not medical advice. Sermorelin products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.

Related peptides

Or compare prices across all peptides.